Adamis Pharmaceuticals Corp. resubmitted a new drug application to the U.S. FDA for epinephrine prefilled syringe product candidate for the emergency treatment of anaphylaxis, an extreme and severe allergic reaction.
The resubmission seeks to address issues raised by the agency in its June complete response letter.